Omega Funds is an international healthcare venture capital firm founded in 2004, with dual headquarters in Boston, Massachusetts and Geneva, Switzerland. The firm is dedicated to supporting the development of transformative therapies that address severe and unmet medical needs, with the aim of delivering meaningful health outcomes to patients globally. Since its founding, Omega has built a strong reputation in the biotech and life sciences sectors, combining company creation with venture investments across the U.S. and Europe.
Omega Funds specializes in the life sciences and healthcare sectors, with a particular emphasis on therapeutics across oncology, immunology, rare diseases, medical devices, and precision medicine.
The firm backs both early-stage and growth-stage companies, including those it helps to create, and typically targets startups that are working on scientifically differentiated platforms with the potential for major clinical impact.
In July 2025, Omega Funds announced the close of its eighth fund, Omega Fund VIII, L.P., with $647 million in capital commitments. The fund received strong support from a mix of new and existing limited partners, reflecting continued confidence in Omega’s track record and strategy.
With Fund VIII, Omega will continue to back innovative biotech companies in the U.S. and Europe that aim to address high-burden diseases with limited treatment options.
The firm intends to maintain its dual model of creating new ventures as well as investing in emerging companies, with check sizes ranging across stages to support pipeline development, clinical trials, and commercialization.
The closing of Fund VIII brings the firm’s total capital raised since inception to $2.5 billion.
Leadership
Omega Funds was founded by Otello Stampacchia, who serves as Founder and Managing Director. He is joined in leadership by Francesco Draetta, also Managing Director.
The team combines deep scientific expertise, operational experience, and global investment insight, allowing Omega to serve as both an investor and a hands-on strategic partner to its portfolio companies.
Investment Strategy
Omega pursues a flexible investment strategy, backing both company creations and external investments at various stages, from early discovery to pre-commercial.
The firm focuses on science-led innovation with clear paths to clinical and regulatory milestones. It often co-invests with top-tier institutional investors and actively supports its portfolio companies through board participation, syndication support, and growth strategy.
Omega’s approach is global, with a focus on impactful innovation, patient outcomes, and scalable business models.
Notable Investments
Omega’s portfolio includes a wide range of companies across therapeutic areas, with many developing first-in-class or best-in-class treatments.
Investments include:
The firm has a consistent track record of helping its companies bring new medicines and medical technologies to market.
Notable Exits
Omega has realized more than 50 exits via mergers and acquisitions, and 47 portfolio companies have gone public.
Notable M&A exits include:
IPO highlights include:
Other
Omega-backed companies have delivered 52 commercialized products to market, a rare feat among venture firms focused on life sciences. This commercial impact underscores the firm’s ability to select and support companies with translational potential and strong clinical relevance. Omega’s dual presence in the U.S. and Europe also gives it unique access to global scientific talent and capital markets.
